$IRD
Opus Genetics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000114036123052749 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.691M $11.94M
YoY Change -95.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.279M $2.060M
YoY Change 59.64% 20.96%
% of Gross Profit
Research & Development $3.841M $3.494M
YoY Change 7.11% 23.25%
% of Gross Profit
Depreciation & Amortization $6.000K $1.000K
YoY Change 500.0% 0.0%
% of Gross Profit
Operating Expenses $7.120M $5.549M
YoY Change 26.24% 22.28%
Operating Profit $6.386M
YoY Change -240.72%
Interest Expense $19.00K $0.00
YoY Change -58.7%
% of Operating Profit 0.0%
Other Income/Expense, Net $613.0K $456.0K
YoY Change 6414.29%
Pretax Income -$4.797M $5.575M
YoY Change -114.0% -223.04%
Income Tax -$2.000K $14.00K
% Of Pretax Income 0.25%
Net Earnings -$4.795M $5.561M
YoY Change -114.13% -222.73%
Net Earnings / Revenue -283.56% 46.59%
Basic Earnings Per Share $0.26
Diluted Earnings Per Share -$0.21 $0.25
COMMON SHARES
Basic Shares Outstanding 22.64M 21.01M
Diluted Shares Outstanding 22.41M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.52M $42.36M
YoY Change 18.35% 203.53%
Cash & Equivalents $50.50M $42.40M
Short-Term Investments $15.00K $10.00K
Other Short-Term Assets $102.0K $51.00K
YoY Change 27.5% -16.39%
Inventory
Prepaid Expenses $997.0K $433.0K
Receivables $926.0K $10.13M
Other Receivables $0.00 $0.00
Total Short-Term Assets $53.95M $54.19M
YoY Change 10.13% 272.14%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $3.000K
YoY Change -100.0% -57.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $3.000K
YoY Change -100.0% -57.14%
TOTAL ASSETS
Total Short-Term Assets $53.95M $54.19M
Total Long-Term Assets $0.00 $3.000K
Total Assets $53.95M $54.19M
YoY Change 10.12% 271.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.153M $1.890M
YoY Change 101.4% 28.75%
Accrued Expenses $1.815M $1.926M
YoY Change 7.78% 57.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.042M $3.909M
YoY Change 46.82% 45.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.042M $3.909M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.042M $3.909M
YoY Change 46.82% 45.26%
SHAREHOLDERS EQUITY
Retained Earnings -$81.47M -$76.67M
YoY Change 13.97% -27.27%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.91M $50.28M
YoY Change
Total Liabilities & Shareholders Equity $53.95M $54.19M
YoY Change 10.12% 271.99%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$4.795M $5.561M
YoY Change -114.13% -222.73%
Depreciation, Depletion And Amortization $6.000K $1.000K
YoY Change 500.0% 0.0%
Cash From Operating Activities $4.548M -$3.000M
YoY Change -84.2% -33.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.599M 5.380M
YoY Change -30091.67% 305.12%
NET CHANGE
Cash From Operating Activities 4.548M -3.000M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 3.599M 5.380M
Net Change In Cash 8.147M 2.380M
YoY Change -71.69% -175.08%
FREE CASH FLOW
Cash From Operating Activities $4.548M -$3.000M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2023Q3 us-gaap Interest Expense
InterestExpense
0
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
9000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20498229
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21446648
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22637600
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34079
dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue, Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
dei City Area Code
CityAreaCode
248
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21117211
CY2023Q1 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001228627
dei Document Type
DocumentType
10-Q
dei Local Phone Number
LocalPhoneNumber
957-9024
CY2023Q3 ocup Financing Costs
FinancingCosts
1328000
CY2022Q3 ocup Financing Costs
FinancingCosts
0
ocup Financing Costs
FinancingCosts
1328000
ocup Financing Costs
FinancingCosts
0
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
CY2022Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19635651
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22405995
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20498229
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21117211
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19635651
CY2022Q1 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
1208000
CY2022Q2 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
1858000
CY2022Q3 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
1362000
CY2022Q3 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
42000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000
CY2022Q3 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4531000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11877000
CY2023Q3 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
6504000
CY2023Q3 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
60000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
573000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5561000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
50282000
ocup Financing Costs
FinancingCosts
1328000
ocup Financing Costs
FinancingCosts
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
61000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
538000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000
us-gaap Stock Issued1
StockIssued1
1022000
us-gaap Stock Issued1
StockIssued1
0
ocup Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
154000
ocup Noncash Or Part Noncash Value Of Derivatives In Connection With Equity Purchase Agreement
NoncashOrPartNoncashValueOfDerivativesInConnectionWithEquityPurchaseAgreement
0
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42400000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 ocup Cash Equivalents Not Eligible For Fdic Coverage
CashEquivalentsNotEligibleForFDICCoverage
42000000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2023Q3 ocup Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
1200000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;">Derivative Liability</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/> </div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separation from the underlying agreement under ASC 815 – <span style="font-style: italic;">Derivatives and Hedging</span>. An embedded derivative that requires separation is accounted for as a separate liability from the host agreement.  The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of comprehensive income (loss) under the fair value change in derivative liability line item. The Company determined that certain features under an equity line financing (See Note 6 <span style="font-style: italic;">— </span>Stockholders’ Equity) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying equity line financing agreement.</div>
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2023Q3 ocup Payments Due Under Cvr Agreement
PaymentsDueUnderCVRAgreement
0
CY2023Q3 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2021Q2 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q3 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
ocup Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
us-gaap Operating Lease Cost
OperatingLeaseCost
27000
us-gaap Operating Lease Cost
OperatingLeaseCost
30000
CY2023Q3 ocup Lessee Non Cancellable Lease Liability To Be Paid One Year Or Less
LesseeNonCancellableLeaseLiabilityToBePaidOneYearOrLess
9000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
433000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1373000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
51000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
80000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
484000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1453000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6000
CY2023Q3 us-gaap Depreciation
Depreciation
1000
CY2022Q3 us-gaap Depreciation
Depreciation
1000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
3000
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
11000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
315000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
470000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
782000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
262000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
208000
CY2023Q3 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
634000
CY2022Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
212000
CY2023Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
500000
CY2022Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
49000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1926000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1684000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
600000
ocup Debt Instrument Number Of Installments
DebtInstrumentNumberOfInstallments
6
CY2023Q3 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.055
us-gaap Interest Expense
InterestExpense
9000
us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
573000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
493000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2799000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1383000
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
0
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
72986
ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2022Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
52225
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
74396
CY2022Q3 ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
1.89
ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
2.04
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
99000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
275000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
154000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y2M12D
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21446648
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20498229
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21117211
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19635651
CY2023Q3 ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
914583
CY2022Q3 ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
ocup Incremental Common Shares Attributable To Options
IncrementalCommonSharesAttributableToOptions
0
CY2023Q3 ocup Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
44764
CY2022Q3 ocup Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
ocup Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
ocup Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
CY2023Q3 ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
CY2022Q3 ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
ocup Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22405995
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20498229
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21117211
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19635651
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0

Files In Submission

Name View Source Status
ocup-20230930_cal.xml Edgar Link unprocessable
ocup-20230930_lab.xml Edgar Link unprocessable
0001140361-23-052749-index-headers.html Edgar Link pending
0001140361-23-052749-index.html Edgar Link pending
0001140361-23-052749.txt Edgar Link pending
0001140361-23-052749-xbrl.zip Edgar Link pending
ef20012451_10q.htm Edgar Link pending
ef20012451_10q_htm.xml Edgar Link completed
ef20012451_ex31-1.htm Edgar Link pending
ef20012451_ex31-2.htm Edgar Link pending
ef20012451_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocup-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
ocup-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ocup-20230930_pre.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending